A 35-year-old woman was diagnosed as triple-negative breast cancer(TNBC)by a core needle biopsy and referred to our hospital. She was diagnosed as cT2N3M1, cStage Ⅳ TNBC because of metastasis in the right axilla, supraclavicular and internal mammary lymph node, and the contralateral supraclavicular lymph node in addition to the primary tumor. No obvious visceral metastasis was observed. Immunohistochemical assay showed SP142 PD-L1-positive and CPS 10 or more by 22C3. The patient was started on atezolizumab+nab-paclitaxel(PTX)therapy, but progression disease(PD)was observed without obvious effect. Pembrolizumab+carboplatin+gemcitabine was started as second-line therapy, and the tumor achieved partial response(PR)but developed PD within 6 months. After that, she was administrated olaparib, but PD was observed, and after the therapy with PTX+bevacizumab, she is now treated with eribulin.
Download full-text PDF |
Source |
---|
Eur J Cardiothorac Surg
March 2025
Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, ; Taipei City, Taiwan.
Objectives: To assess the prognostic impact of adequate lymphadenectomy and determine the optimal nodal assessment for different clinical stages of lung cancer.
Methods: We retrospectively reviewed 1214 patients with clinical stage I-III non-small cell lung cancer who had preoperative PET/CT and curative surgery (2006-2017). Patients were categorized based on whether they had adequate [R0] or inadequate lymphadenectomy [R(un)].
Interdiscip Cardiovasc Thorac Surg
March 2025
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Objectives: This study aimed to explore the possibility of positron emission tomography/computed tomography (PET-CT) in identifying histological classification of thymic tumors.
Methods: Patients diagnosed as thymic tumors and accepted PET-CT scans were included. Thymic tumors were classified into three subgroups: low risk thymoma (A, AB and B1), high risk thymoma (B2, B3) and thymic carcinoma (TC).
Eur J Cardiothorac Surg
March 2025
Department of Cardiothoracic Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY 525 E 68 St, M-404, New York, NY 10065, USA.
Objectives: Compare oncologic outcomes between single-segment and multi-segment resections in patients with clinical stage IA1 and IA2 non-small cell lung cancer.
Methods: A retrospective review (2011-2022) was conducted using a prospectively maintained database. Patients undergoing anatomical segmentectomy for clinical stage IA ≤ 2 cm non-small cell lung cancers were included.
Br J Radiol
March 2025
Department of Medical Ultrasound, Shandong Medicine and Health Key Laboratory of Abdominal Medical Imaging, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
Objectives: To develop a deep learning (DL) model based on ultrasound (US) images of lymph nodes for predicting cervical lymph node metastasis (CLNM) in postoperative patients with differentiated thyroid carcinoma (DTC).
Methods: Retrospective collection of 352 lymph nodes from 330 patients with cytopathology findings between June 2021 and December 2023 at our institution. The database was randomly divided into the training and test cohort at an 8:2 ratio.
J Immunol
March 2025
Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI, United States.
B cell depletion is an efficacious therapy for multiple sclerosis, but its long-term safety profile in the gastrointestinal tract has not been specifically studied. This is of importance because the gut is the largest reservoir of IgA in the body, which maintains gut homeostasis in part by regulating the composition of the gut microbiota. This was addressed by development of a prolonged B cell depletion model using human CD20 transgenic mice and B cell depletion with the anti-human CD20 antibodies rituximab, a humanized mouse monoclonal, and 2H7, the mouse precursor to ocrelizumab.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!